Congenital Adrenal Hyperplasia Medical Services in China

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive genetic disorders characterized by impaired cortisol biosynthesis due to enzymatic defects in the adrenal steroidogenesis pathway—most commonly 21-hydroxylase deficiency (accounting for >90% of cases). This enzymatic blockade leads to cortisol deficiency, compensatory adrenocorticotropic hormone (ACTH) overproduction, and adrenal hyperplasia. Concurrently, precursor accumulation shunts into androgen biosynthesis, resulting in prenatal or postnatal androgen excess. In classic CAH, severe enzyme deficiency manifests in infancy with life-threatening salt-wasting crises (hyponatremia, hyperkalemia, hypovolemic shock) or virilization in genetically female infants (ambiguous genitalia), while non-classic CAH presents later with premature pubarche, hirsutism, oligomenorrhea, infertility, or acne—often misdiagnosed as PCOS. Epidemiologically, classic CAH occurs in approximately 1:15,000 live births globally, with higher prevalence in certain founder populations (e.g., Ashkenazi Jews, Yupik Alaskans); non-classic CAH is more common (~1:200–1:1,000 in some ethnic groups). Risk factors include consanguinity and family history; carrier frequency is ~1:50–1:70 in general populations. From a reproductive medicine perspective, CAH profoundly impacts fertility: women may experience anovulation, chronic anovulatory cycles, and ovarian hyperandrogenism leading to subfertility or recurrent pregnancy loss; men may develop testicular adrenal rest tumors (TARTs), oligospermia, or reduced testosterone. Psychosocial burden includes gender identity concerns in severely virilized females, anxiety around fertility, lifelong medication adherence challenges, and stigma related to hirsutism or menstrual dysfunction. Quality of life is further compromised by chronic fatigue, metabolic comorbidities (insulin resistance, obesity), and increased risk of cardiovascular disease with suboptimal glucocorticoid replacement. Early diagnosis via newborn screening (17-OHP assay), timely hormonal replacement (hydrocortisone, fludrocortisone), and multidisciplinary care—including endocrinology, reproductive endocrinology, psychology, and genetics—are essential to normalize growth, preserve fertility, prevent adrenal crises, and support psychosocial well-being across the lifespan.

Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder of adrenal steroidogenesis characterized by impaired cortisol biosynthesis, leading to compensatory adrenocorticotropic hormone (ACTH) hypersecretion, adrenal hyperplasia, and accumulation of precursor steroids—most notably androgens. The overwhelming majority (>95%) of CAH cases result from biallelic pathogenic variants in the *CYP21A2* gene, which encodes 21-hydroxylase, a cytochrome P450 enzyme critical for converting progesterone to deoxycorticosterone and 17-hydroxyprogesterone to 11-deoxycortisol. Deficiency in this enzyme causes shunting of steroid precursors toward the androgen synthesis pathway, resulting in prenatal virilization in genetically female fetuses and postnatal manifestations including rapid growth, advanced bone age, precocious puberty, hirsutism, oligo-amenorrhea, and infertility—particularly relevant to reproductive medicine. Less common enzymatic defects include 11β-hydroxylase deficiency (*CYP11B1*), 3β-hydroxysteroid dehydrogenase type 2 deficiency (*HSD3B2*), steroidogenic acute regulatory protein (StAR) deficiency (*STAR*), and cytochrome P450 oxidoreductase deficiency (*POR*); each presents with distinct hormonal profiles and reproductive implications, such as hypertension in 11β-hydroxylase deficiency or primary ovarian insufficiency in StAR deficiency.

Genetic factors are central to CAH etiology. It follows strict autosomal recessive inheritance: affected individuals inherit one pathogenic variant from each asymptomatic carrier parent. Carrier frequency varies by population—approximately 1:50–1:70 in the general Caucasian population, but markedly higher in certain ethnic groups (e.g., ~1:27 in Ashkenazi Jews, ~1:30 in Yupik Alaskans). Over 200 *CYP21A2* variants have been identified, including large gene deletions, chimeric *CYP21A1P/CYP21A2* genes, and missense/nonsense mutations; genotype-phenotype correlations exist, with null alleles typically associated with the severe salt-wasting form, while milder variants (e.g., p.V281L) correlate with non-classic CAH (NCAH). NCAH, often diagnosed in adolescence or adulthood, is a significant contributor to hyperandrogenic disorders in women—including polycystic ovary syndrome (PCOS)-like phenotypes, anovulation, and recurrent pregnancy loss—making it a key differential diagnosis in reproductive endocrinology.

There are no known environmental triggers that initiate CAH, as it is a germline genetic disorder present from conception. However, environmental and iatrogenic factors may modulate clinical expression and reproductive outcomes. Chronic glucocorticoid overtreatment—common in poorly monitored CAH management—can induce iatrogenic Cushing’s syndrome, exacerbating metabolic syndrome, insulin resistance, and ovarian suppression. Conversely, undertreatment leads to persistent hyperandrogenism and chronic ACTH-driven adrenal hyperplasia, increasing risk of adrenal rest tumors and fertility impairment. Psychosocial stressors, obesity, and insulin resistance may amplify hyperandrogenic symptoms and worsen menstrual dysfunction, particularly in NCAH. While prenatal environmental exposures (e.g., endocrine-disrupting chemicals) do not cause CAH, they may theoretically compound androgen excess or alter HPA axis set points, though robust epidemiologic evidence is lacking.

Key risk factors for adverse reproductive outcomes include delayed or inaccurate diagnosis—especially in mild or atypical NCAH—leading to prolonged unopposed androgen exposure and irreversible consequences such as clitoromegaly (in classic forms), premature epiphyseal fusion, and anovulatory infertility. Poor adherence to glucocorticoid replacement, suboptimal dosing regimens (e.g., lack of circadian dosing or inadequate stress-dose coverage), and failure to monitor androgen biomarkers (e.g., 17-OHP, androstenedione, DHEA-S) contribute significantly to long-term morbidity. In women with classic CAH, risks include reduced ovarian reserve, higher prevalence of uterine anomalies (e.g., vaginal septa), and increased rates of pregnancy complications—such as gestational hypertension, preterm delivery, and fetal growth restriction—necessitating multidisciplinary preconception counseling and close obstetric-endocrine co-management. Male patients face risks of testicular adrenal rest tumors (TARTs), which can impair spermatogenesis and testosterone production if undetected. Family history remains the strongest clinical risk indicator; first-degree relatives of affected individuals warrant cascade genetic testing and biochemical screening, especially prior to family planning. Early molecular diagnosis via newborn screening (where implemented) and targeted *CYP21A2* sequencing in hyperandrogenic women improves reproductive prognostication and enables timely intervention.

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive disorders caused by enzymatic defects in cortisol biosynthesis within the adrenal cortex. The most common form—accounting for over 90% of cases—is 21-hydroxylase deficiency (CYP21A2 gene mutations), followed by rarer variants including 11β-hydroxylase, 17α-hydroxylase, and 3β-hydroxysteroid dehydrogenase deficiencies. In the context of Reproductive Medicine, CAH presents with profound implications for sexual development, fertility, hormonal homeostasis, and long-term reproductive health. Early symptoms often manifest in infancy or early childhood and may be subtle or life-threatening. In classic salt-wasting CAH (21-OHD), neonates may present with vomiting, poor feeding, lethargy, dehydration, hypotension, hyponatremia, hyperkalemia, and metabolic acidosis within the first 1–4 weeks of life—constituting an adrenal crisis requiring urgent glucocorticoid and mineralocorticoid replacement. Female infants frequently exhibit ambiguous genitalia due to prenatal androgen excess: clitoromegaly, labial fusion, and urogenital sinus formation—often prompting referral to Reproductive Medicine or Pediatric Endocrinology for sex assignment evaluation and surgical planning. Male infants typically have normal-appearing external genitalia but may display penile enlargement, advanced bone age, and premature pubarche—signs easily mistaken for idiopathic precocious puberty. Non-classic CAH (NCAH), usually milder and later-onset, commonly presents in late childhood, adolescence, or adulthood with signs of hyperandrogenism: hirsutism, acne, oligomenorrhea or amenorrhea, anovulation, infertility, and polycystic ovary morphology on ultrasound—mimicking polycystic ovary syndrome (PCOS). In males, NCAH may cause premature adrenarche, oligospermia, or reduced testicular volume due to chronic gonadotropin suppression from elevated adrenal androgens.

Typical symptoms reflect the underlying enzymatic block and resultant hormone imbalances. In 21-OHD and 11β-OHD, cortisol deficiency triggers compensatory ACTH hypersecretion, leading to adrenal hyperplasia and accumulation of upstream steroid precursors—particularly androgens (e.g., androstenedione, testosterone) and, in 11β-OHD, deoxycorticosterone (DOC), which causes hypertension and hypokalemia. Thus, typical manifestations include progressive virilization: deepening voice, temporal hair recession, increased muscle mass, and clitoromegaly in females; in males, accelerated linear growth with premature epiphyseal fusion resulting in short adult stature. Hypertension is characteristic of 11β-OHD and 17α-OHD (due to mineralocorticoid excess), whereas salt-wasting occurs exclusively in severe 21-OHD and 3β-HSD deficiency. In 17α-OHD and 17,20-lyase deficiency, impaired sex steroid synthesis leads to undervirilization in 46,XY individuals (e.g., micropenis, cryptorchidism, hypospadias) and primary amenorrhea with lack of breast development in 46,XX individuals—highlighting critical diagnostic overlap with disorders of sex development (DSD).

Accompanying symptoms are multifactorial and often chronic. Chronic hyperandrogenism contributes to insulin resistance, dyslipidemia, central obesity, and increased risk of metabolic syndrome—particularly in women with NCAH. Psychological comorbidities—including anxiety, depression, body image distress, and sexual dysfunction—are prevalent, especially among women undergoing genital surgery or struggling with infertility. Sleep disturbances, fatigue, and reduced quality of life correlate with suboptimal glucocorticoid dosing (overtreatment causing Cushingoid features vs. undertreatment permitting androgen excess). In adolescents and adults, menstrual irregularity, anovulatory infertility, and recurrent pregnancy loss are frequent reproductive concerns. Men may experience decreased libido, erectile dysfunction, or subfertility secondary to suppressed intratesticular testosterone and altered spermatogenesis.

Complications arise from both disease pathophysiology and therapeutic interventions. Adrenal crises remain the most acute, potentially fatal complication—triggered by intercurrent illness, trauma, or inadequate stress-dose glucocorticoid coverage. Long-term complications include short stature (from premature epiphyseal closure), osteopenia/osteoporosis (due to chronic glucocorticoid exposure and/or androgen deficiency), hypertension (in mineralocorticoid-excess forms), and cardiovascular morbidity. Women with classic CAH face markedly increased risks of ovarian adrenal rest tumors (OARTs)—benign but hormonally active lesions that may exacerbate hyperandrogenism and impair ovarian reserve. Infertility persists despite hormonal control in up to 50–70% of women with classic CAH, attributable to anatomical factors (e.g., vaginal stenosis, uterine hypoplasia), hypothalamic-pituitary-gonadal axis dysregulation, and chronic anovulation. Pregnancy outcomes are high-risk: increased rates of gestational hypertension, preeclampsia, preterm birth, low birth weight, and fetal adrenal suppression if maternal dexamethasone is used empirically for prenatal sex selection (now discouraged outside research protocols).

Diagnosis relies on biochemical and genetic assessment. First-line testing is morning serum 17-hydroxyprogesterone (17-OHP): markedly elevated (>10,000 ng/dL) in classic 21-OHD; moderately elevated (2,000–10,000 ng/dL) in non-classic forms. ACTH stimulation testing (cosyntropin test) enhances sensitivity, particularly in borderline or NCAH cases. Additional markers include elevated androstenedione, testosterone, DHEA-S, and renin activity (high in salt-wasting, low in 11β-OHD). Plasma renin activity (PRA) and aldosterone help differentiate salt-wasting from simple virilizing forms. Genetic testing (CYP21A2 sequencing and deletion analysis) confirms diagnosis, enables carrier screening, and informs genetic counseling. Newborn screening programs detect classic CAH via heel-prick 17-OHP assays, enabling life-saving early intervention.

Differential diagnosis is essential given phenotypic overlap. In females with virilization and amenorrhea, PCOS is the most common mimic—but lacks elevated 17-OHP and exhibits normal or mildly elevated androstenedione without ACTH responsiveness. Other considerations include ovarian or adrenal tumors (typically unilateral, rapidly progressive, with very high testosterone or DHEA-S), Cushing’s syndrome (hypercortisolism with suppressed ACTH), and other DSDs such as 5α-reductase deficiency or androgen insensitivity syndrome (normal or elevated testosterone with absent virilization). In males with precocious puberty, differentials include central precocious puberty, testotoxicosis (LHCGR mutations), and McCune-Albright syndrome. Hypertension with hypokalemia necessitates exclusion of primary aldosteronism, Liddle syndrome, and apparent mineralocorticoid excess. Accurate distinction guides management: tumor resection versus lifelong medical therapy, fertility preservation strategies, and multidisciplinary care involving Reproductive Endocrinology, Pediatric Endocrinology, Urology, Psychology, and Genetics.

Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder characterized by enzymatic defects in cortisol biosynthesis, most commonly due to 21-hydroxylase deficiency (95% of cases). In the Department of Reproductive Medicine, CAH management focuses on optimizing hormonal homeostasis, preserving fertility potential, preventing virilization or undervirilization, and supporting psychosocial well-being—particularly in individuals with disorders of sex development (DSD), such as 46,XX females with prenatal androgen excess or 46,XY males with atypical genital phenotypes. Treatment is lifelong, multidisciplinary, and individualized according to genotype, phenotype, age at diagnosis, and reproductive goals.

Conservative treatment forms the cornerstone of CAH management and emphasizes continuous endocrine surveillance and lifestyle integration. It includes regular monitoring of serum 17-hydroxyprogesterone (17-OHP), androstenedione, testosterone, renin activity, electrolytes, growth velocity, bone age, and bone mineral density. For women of reproductive age, assessment of ovarian reserve (AMH, AFC), menstrual cyclicity, and pelvic ultrasound for adrenal rest tumors or polycystic ovarian morphology is essential. Conservative strategies also involve nutritional counseling to mitigate metabolic risks associated with chronic glucocorticoid use—including insulin resistance, central adiposity, and dyslipidemia—as well as psychological support to address body image concerns, gender identity development, and sexual health. Fertility counseling should begin in adolescence: while spontaneous conception is possible in classic CAH, especially with optimized control, subfertility is common due to chronic hyperandrogenism, anovulation, and hypothalamic-pituitary-ovarian axis dysregulation. In men, testicular adrenal rest tumors (TARTs) may impair spermatogenesis; therefore, annual scrotal ultrasound and semen analysis are recommended starting at puberty.

Pharmacotherapy remains the primary medical intervention. Glucocorticoid replacement—typically hydrocortisone (10–15 mg/m²/day in children, 15–25 mg/day in adults, divided into two or three doses)—is titrated to suppress adrenal androgen overproduction while avoiding Cushingoid side effects. In adults, longer-acting agents like prednisolone or dexamethasone may be considered for improved adherence, though dexamethasone carries higher risks of osteoporosis and metabolic complications and is avoided in pregnancy unless strictly indicated for prenatal therapy. Mineralocorticoid replacement (fludrocortisone 0.05–0.2 mg/day) is mandatory in salt-wasting forms to maintain sodium balance and suppress renin. During illness, injury, or surgery, patients require stress-dose glucocorticoids (e.g., hydrocortisone 50–100 mg IV/IM) to prevent adrenal crisis—a life-threatening emergency. For women with persistent hyperandrogenism despite optimal glucocorticoid dosing, adjunctive anti-androgens (e.g., spironolactone 50–200 mg/day) or combined oral contraceptives may be used cautiously, recognizing their limited evidence base in CAH and potential interference with adrenal hormone monitoring. Newer agents under investigation include CRH receptor antagonists and selective 11β-HSD1 inhibitors, though none are yet standard-of-care.

Surgical intervention is reserved for specific indications and always follows comprehensive multidisciplinary evaluation—including endocrinology, reproductive medicine, urology, psychology, and ethics consultation. In 46,XX infants with severe virilization (Prader III–V), feminizing genitoplasty—comprising clitoral reduction (notectomy or recession) and vaginoplasty—may be performed in early infancy (3–12 months) when tissue vascularity and healing capacity are optimal. However, current international consensus strongly advocates deferring irreversible surgery until the patient can participate meaningfully in decision-making, except in cases of urinary obstruction or recurrent infection. In adolescents and adults, revisional surgery may address functional concerns (e.g., vaginal stenosis, dyspareunia) or cosmetic dissatisfaction. For males with TARTs causing pain, obstruction, or progressive testicular damage, surgical excision or debulking may be indicated, though fertility preservation via sperm retrieval prior to intervention is prioritized. Laparoscopic adrenalectomy is rarely performed and only in refractory, unilateral, non-metastatic adrenal cortical neoplasms misdiagnosed initially as CAH-related hyperplasia.

Treatment advantages in China reflect rapid advancements in integrated care delivery. Major tertiary hospitals—especially those affiliated with universities in Beijing, Shanghai, Guangzhou, and Chengdu—offer centralized CAH registries linked to national newborn screening programs, enabling diagnosis within days of birth. Genotype-phenotype correlation is routinely performed using next-generation sequencing panels covering all known CAH-associated genes (CYP21A2, CYP11B1, HSD3B2, etc.), facilitating prognostication and family counseling. Reproductive Medicine Departments collaborate closely with Assisted Reproductive Technology (ART) centers: ovulation induction with low-dose gonadotropins or letrozole is increasingly successful in women with CAH, and ICSI with preimplantation genetic testing (PGT-M) is available for couples seeking to avoid transmission. Moreover, China’s National Health Insurance now covers lifelong hydrocortisone and fludrocortisone for confirmed CAH, significantly improving medication adherence. Telemedicine platforms enable longitudinal follow-up for rural patients, and standardized clinical pathways—endorsed by the Chinese Society of Endocrinology and the Chinese Medical Association of Reproductive Medicine—ensure evidence-based, equitable care across regions.

Recovery and long-term self-management advice emphasize empowerment through education. Patients and families should receive written emergency action plans detailing sick-day rules, injectable hydrocortisone administration, and when to seek urgent care. Annual dual-energy X-ray absorptiometry (DXA) scans are advised after age 18 to monitor bone health. Regular gynecologic evaluation—including transvaginal ultrasound and cervical cytology—is critical for women, particularly those with a history of vaginal surgery or chronic anovulation. Men should undergo annual testicular ultrasound and hormonal profiling. Psychological resilience is fostered through peer support networks (e.g., the China CAH Alliance) and access to certified sexologists and reproductive counselors. Pregnancy requires preconception optimization: glucocorticoid doses are adjusted to physiological needs, and close maternal-fetal monitoring mitigates risks of preeclampsia, gestational diabetes, and fetal adrenal suppression. With consistent, expert-guided care, individuals with CAH achieve normal life expectancy, healthy pregnancies, and fulfilling reproductive lives—underscoring that optimal outcomes depend not solely on pharmacotherapy, but on sustained, compassionate, and patient-centered reproductive medicine partnership.